Clinical Trials Browser

Genital Neoplasms, Female × Ipilimumab × 90 days × Clear all

NCT04969887 2026-02-27

MOST-CIRCUIT

Phase 2 Active not recruiting

Genital Neoplasms, Female, Neuroendocrine Tumors